title: [Therapeutic advances for indolent lymphomas].
abstract: New therapeutic strategies for indolent lymphomas are described. Relapsed or advanced staged follicular lymphoma is assumed to have an indolent course when compared with intermediate- and high-grade NHL. Although treatment of low-grade follicular lymphomas with standard chemotherapeutic regimens is characteristically associated with a high initial response rate, the clinical course consists of a pattern of repeated relapse. Subsequent remissions occur, but at a progressively lower rate and with a shorter duration. Patients eventually succumb to the disease or its complications with a median survival of approximately 6.2 years. For these reasons, novel therapeutic agents and strategies need to be evaluated in this group of patients. Recently, high-dose chemoradiotherapy with autologous hematopoietic stem cell transplantation with ex vivo purging method was reported to be very effective therapeutic strategy. Very promising reports of chimeric anti-CD20 monoclonal antibody(rituximab), radioimmunotherapy by radioisotope-conjugated monoclonal antibodies, interferon, and allogeneic mini-transplantation followed by non-myeloablative preconditioning regimens are reviewed. Recent therapeutic approaches for other subtypes of indolent lymphomas including MALT and mantle cell lymphoma are also reviewed.
authors.forename: M
authors.initials: M
authors.lastname: Ogura
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016465:Bone Marrow Purging; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000628:therapy; D018442:Lymphoma, B-Cell, Marginal Zone / Q000628:therapy; D008224:Lymphoma, Follicular / Q000628:therapy; D020522:Lymphoma, Mantle-Cell / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D016499:Radioimmunotherapy; D000069283:Rituximab; D014182:Transplantation, Autologous
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D000069283:Rituximab